Welcome to our dedicated page for Cyclacel Pharma news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharma stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company whose news flow centers on cancer drug development, capital markets activity and strategic transactions. The company publicly describes its focus as developing cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, with its lead candidate plogosertib, a PLK1 inhibitor, being evaluated in patients with solid tumors and hematological malignancies.
News updates for CYCC often include clinical and preclinical developments related to plogosertib. Cyclacel has highlighted independent studies showing that biliary tract cancer and fibrolamellar hepatocellular carcinoma cells can be sensitive to PLK1 inhibition with plogosertib, as well as early Phase 1 data where oral plogosertib was reported to be well tolerated without dose-limiting toxicity in several dosing schedules. These items give investors and researchers insight into how external and internal data may shape the company’s oncology pipeline.
Cyclacel’s news also covers financial results and funding events, such as quarterly earnings updates, private placements of convertible preferred stock with accompanying warrants, and declarations of quarterly cash dividends on its 6% Convertible Exchangeable Preferred Stock. In addition, the company has issued releases on Nasdaq listing matters, including notices about minimum bid price compliance and announcements of reverse stock splits that affect the share structure while maintaining the CYCC ticker on The Nasdaq Capital Market.
Another recurring theme in Cyclacel news is strategic alternatives and corporate transactions. The company has discussed evaluating options to continue as a going concern and has announced an Exchange Agreement to acquire Fitters Sdn. Bhd., a Malaysia-based fire safety and protective equipment business, in a share and cash transaction subject to approvals. For investors tracking CYCC, following these news items helps monitor both the scientific progress of plogosertib and the company’s evolving capital structure and business direction.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported its Q2 2025 financial results and significant corporate developments. The company entered a major share exchange agreement with FITTERS Diversified Berhad, where Fitters Parent will exchange 100% of FITTERS Sdn. Bhd. for approximately 19.99% of Cyclacel's common stock, plus $1,000,000 in cash consideration.
Key financial highlights include cash position of $4.3 million as of June 30, 2025, up from $3.2 million in December 2024. The company raised $3 million through Series F Convertible Preferred Stock offering and implemented a 1-for-15 reverse stock split to meet Nasdaq requirements. Q2 2025 saw reduced R&D expenses of $0.1 million (vs $2.0 million in Q2 2024) and lower G&A expenses of $1.2 million (vs $1.6 million in Q2 2024), resulting in a net loss of $1.3 million.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) highlighted promising preclinical data showing the effectiveness of their drug plogosertib in treating biliary tract cancer (BTC). The study, published in Cancer Research, demonstrated that BTC cell lines were sensitive to plogosertib both as a standalone treatment and in combination therapy.
The research revealed that plogosertib works by promoting mitotic checkpoint complex formation, leading to mitotic arrest and cancer cell death. Importantly, the study identified BUBR1 as a potential biomarker for treatment effectiveness, with high BUBR1-expressing cells showing increased sensitivity to the drug. The findings suggest that targeting PLK1 with plogosertib could be an effective strategy for BTC treatment, particularly when combined with ATR inhibitors.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has issued a statement addressing recent unusual stock price movements. The company confirmed that there are no material developments or changes to its operating or financial condition that would explain the significant volume and price fluctuations observed on July 15, 2025.
The biopharmaceutical company emphasized that aside from its previously announced amendment to the Exchange Agreement with FITTERS Diversified Berhad on July 7, 2025, there have been no material adverse changes to its business operations, strategy, or prospects.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced the publication of preclinical data demonstrating the effectiveness of their drug plogosertib in treating fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer affecting young people with no approved treatments.
The study, published in the journal Gut, revealed that FLC cells are highly sensitive to PLK1 inhibition by plogosertib. The research showed that the DNAJ-PKAc fusion oncoprotein, which drives FLC progression, interacts with PLK1 at the centrosome. Notably, plogosertib demonstrated significant reduction in FLC growth while sparing normal liver cells in both in vitro and in vivo models.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has amended its Exchange Agreement with FITTERS Diversified Berhad. The amended agreement includes a new cash consideration of $1 million in addition to the previously agreed stock exchange and extends the final date to September 30, 2025.
Under the Transaction, Cyclacel will acquire all ordinary shares of Fitters Sdn. Bhd., making it a wholly-owned subsidiary, in exchange for Cyclacel common stock representing 19.99% of outstanding shares. The deal requires approval from both companies' stockholders and has received unanimous board approval from all parties involved.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-15 reverse stock split effective July 7, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L876.
Following the split, every 15 shares will automatically convert into one share, with fractional shares being rounded up or down. The total number of outstanding shares will decrease from 23,759,475 to 1,583,965. The reverse split, approved by both the board and stockholders, will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-16 reverse stock split effective May 12, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L884.
Following the split, every 16 shares will automatically convert into one share, with fractional shares being rounded up or down. The pre-split share count of 356,357,531 will be reduced to 22,272,346 post-split. The reverse split was approved by both the board of directors and stockholders, and will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.
FAQ
What is the current stock price of Cyclacel Pharma (CYCC)?
What is the market cap of Cyclacel Pharma (CYCC)?
